Please login to the form below

Not currently logged in

beta thalassaemia

This page shows the latest beta thalassaemia news and features for those working in and with pharma, biotech and healthcare.

BMS scores EU okay for first-in-class anaemia drug Reblozyl

BMS scores EU okay for first-in-class anaemia drug Reblozyl

Originally developed by Acceleron as ACE-536 and licensed by Celgene in 2011, Reblozyl was approved by the FDA for anaemia associated with beta thalassaemia last year, and for the MDS ... The beta thalassemia market could prove tougher to crack because

Latest news

More from news
Approximately 4 fully matching, plus 20 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia